Brookline Capital analyst Kemp Dolliver downgrades Dare Bioscience (NASDAQ:DARE) from Buy to Hold.
Brookline Capital Downgrades Dare Bioscience to Hold
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.